Syngene International Limited (NSE:SYNGENE)
448.00
+6.00 (1.36%)
Jun 1, 2026, 3:30 PM IST
Syngene International Revenue
In the fiscal year ending March 31, 2026, Syngene International had annual revenue of 37.39B INR with 2.64% growth. Syngene International had revenue of 10.37B in the quarter ending March 31, 2026, with 1.82% growth.
Revenue
37.39B
Revenue Growth
+2.64%
P/S Ratio
4.77
Revenue / Employee
5.72M
Employees
6,533
Market Cap
178.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 37.39B | 963.00M | 2.64% |
| Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
| Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
| Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
| Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 277.12B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 105.60B |
| Sagility | 72.91B |
| NATCO Pharma | 43.76B |
| Eris Lifesciences | 31.15B |
| Pfizer | 25.20B |
Syngene International News
- 4 weeks ago - Top gainers in morning trade: HFCL at ₹116.03 up 8.34%, syngene international at ₹467.65 up 8.21%, gujarat fluorochemicals at ₹3,602.00 up 7.16% - Business Upturn
- 4 weeks ago - Syngene International Transcript: Q4 25/26 - Transcripts
- 4 weeks ago - Syngene International Quarterly report: Q4 2026 - Filings
- 4 weeks ago - Syngene International Slides: Q4 2026 - Filings
- 4 weeks ago - Syngene stock jumps 8% despite profit falling 19% — the market is clearly looking past one - Business Upturn
- 2 months ago - Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Benzinga
- 2 months ago - Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International - Nasdaq
- 4 months ago - Syngene International shares fall sharply over 7% today: Details here - Business Upturn